LITESPARK-011: what clinicians are saying
belzutifan plus lenvatinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy · NCT04586231 ↗ · Phase 3 · Merck Sharp & Dohme LLC
One physician reads LITESPARK-011 as grounds to change practice because responses lasted longer, while acknowledging that survival benefit remains unproven. Another physician favors earlier belzutifan–lenvatinib because patients may never reach later treatment lines. A medical oncologist still leans toward single-agent treatment for most patients, citing difficulty delivering lenvatinib, and wants cardiac toxicity better understood. Comparisons with lenvatinib–everolimus and sequential treatment remain unresolved.
Created with AI · how we check it
- edition 1
- commentary checked Nov 20, 2026
- 1,422 verified statements
This edition $1,950, with MCP access for your AI agent. Get this report
12 findings, and what sits behind each
01. LITESPARK-011: where speakers split on adoption without a proven OS benefit
4 of the report's 61 cited clinicians · 7 statements from 6 speakers in 6 sources, 2 of them podcasts or videos · 9 passages
Limitations recorded: 2.
Draws on: Primary endpoint: Overall Survival (OS), Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Design and conduct.
02. Durable responses and PROs: where speakers split on evidence of patient benefit
18 of the report's 61 cited clinicians · 78 statements from 27 speakers in 41 sources, 19 of them podcasts or videos · 61 passages
Limitations recorded: 3.
Draws on: Secondary endpoint: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Secondary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Primary endpoint: Overall Survival (OS).
03. Care: where speakers split on toxicity but weigh fitness, dosing and heart checks
27 of the report's 61 cited clinicians · 145 statements from 37 speakers in 66 sources, 25 of them podcasts or videos · 114 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Secondary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs), Secondary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE), The comparison, Primary endpoint: Overall Survival (OS), Design and conduct.
04. IMDC risk: why some speakers keep subgroup signals exploratory and seek biomarkers
11 of the report's 61 cited clinicians · 83 statements from 16 speakers in 31 sources, 17 of them podcasts or videos · 79 passages
Limitations recorded: 3.
Draws on: Secondary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs), Safety and tolerability.
05. Belzutifan: what speakers say
7 of the report's 61 cited clinicians · 23 statements from 9 speakers in 13 sources, 8 of them podcasts or videos · 26 passages
Limitations recorded: 4.
Draws on: Safety and tolerability.
06. Active control: why most speakers value it, but some flag evidence limits
13 of the report's 61 cited clinicians · 78 statements from 20 speakers in 37 sources, 22 of them podcasts or videos · 67 passages
Limitations recorded: 2.
Draws on: Design and conduct, Primary endpoint: Overall Survival (OS), Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Population and setting, The comparison, Secondary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Secondary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs).
07. HIF-2α pairings: why most speakers seek validation as some weigh intensity
30 of the report's 61 cited clinicians · 196 statements from 42 speakers in 72 sources, 26 of them podcasts or videos · 150 passages
Limitations recorded: 2.
Draws on: Secondary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE).
Beyond the trial population
08. Drugs or trials: how clinicians weigh urgency, AEs, access, later lines and evidence
12 of the report's 61 cited clinicians · 73 statements from 12 speakers in 10 sources, 7 of them podcasts or videos · 100 passages
Limitations recorded: 6.
09. IO: most clinicians weigh timing, withdrawal and local Rx but oppose routine reuse at PD
11 of the report's 61 cited clinicians · 140 statements from 12 speakers in 18 sources, 14 of them podcasts or videos · 120 passages
Limitations recorded: 2.
10. Belzutifan: why most clinicians favor ESAs as most weigh thresholds and risk
10 of the report's 61 cited clinicians · 85 statements from 10 speakers in 12 sources, 11 of them podcasts or videos · 73 passages
Limitations recorded: 3.
11. Hypoxia: where clinicians split on holds but use lung checks, oximetry and guidance
8 of the report's 61 cited clinicians · 47 statements from 8 speakers in 8 sources, all podcasts or videos · 43 passages
Limitations recorded: 2.
12. Belzutifan: some clinicians seek markers; some question a VHL-negative veto
6 of the report's 61 cited clinicians · 61 statements from 7 speakers in 8 sources, 7 of them podcasts or videos · 52 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 12
4 of the report's 61 cited clinicians
LITESPARK-011: where speakers split on adoption without a proven OS benefit
7 statements from 6 speakers in 6 sources, 2 of them podcasts or videos
6 of the 6 named speakers in this finding take a side on this question: 5 on one side, 2 on the other, 1 on both
- 7
- statements
- 9
- passages
- 6
- sources
- 6
- speakers
What the statements areViews 7Questions and uncertainty 0Clinical experience 0Comparisons 0Restated results and context 0Statement-to-passage links (a passage can back several statements)Supporting a statement 9Giving context 0Recorded with the findingLimitations: 2
4 posts and articles · 2 podcasts and video
Draws on: Primary endpoint: Overall Survival (OS), Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR), Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
5 of the 12 findings and 345 of the 1,422 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Medical oncologist · ex-US
Podcast · Apr 2026
Staff page checked · finding 3
A medical oncologist does not think the trial's approach is for everybody because adding belzutifan brings different side effects, but expects some patients to choose the better efficacy despite those side effects.
Physician · US
Video · Mar 2026
NPI checked · finding 4
A physician regards belzutifan plus lenvatinib as a meaningful new option for post-PD-L1 RCC, while emphasizing patient selection and suggesting favorable- and intermediate-risk patients appear to gain the most.
Physician · US
Podcast · Mar 2026
NPI checked · finding 5
A physician might apply the same full-dose, fit-patient logic to lenvatinib–belzutifan in the future, without those dose reductions.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations (13)
AE, adverse event; BICR, blinded independent central review; DOR, duration of response; HCP, healthcare professional; IO, immuno-oncology; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; RCC, renal cell carcinoma; RECIST, Response Evaluation Criteria in Solid Tumors.
The full LITESPARK-011 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say would justify adopting belzutifan plus lenvatinib as a standard for advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy—PFS and response balanced against toxicity, or mature overall survival evidence?
From finding F1 (7 statements from 6 speakers in 6 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 461commentary sources screened
- 239sources cited by verified statements
- 95named in screened sources
- 92speakers cited in the report
- 75cited speakers with a verified identity
61 cited clinicians, speakers with a confirmed clinical role, of them 60 physicians. By role and specialty:
- 36 physician, Medical oncology
- 18 physician, specialty not confirmed
- 2 physician, Hematology and oncology
- 2 physician, Urology
- 1 pharmacist
- 1 physician, Internal medicine
- 1 physician, Surgical oncology
Also in the sources: 28 organizational or shared accounts, not counted as people.
- 1,422verified statements, each linked to its source
- 672of them from speakers with a confirmed clinical role
- 12findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 17 sections | Paid |
| Verified statements with short source quotes and links | 1,422 | Paid |
| Who said each statement: the cited speakers | 92 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 61 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 75 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 22 | Free |
| Sources with links | 239 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
22 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | 14 | 13 |
| Primary endpoint: Overall Survival (OS) | 18 | 12 |
| Secondary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | 12 | 12 |
| Secondary endpoint: Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) | 12 | 11 |
| Secondary endpoint: Number of Participants Who Experienced One or More Adverse Events (AEs) | 17 | 14 |
| Secondary endpoint: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 8 | 7 |
| Population and setting | 21 | 12 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 21 | 11 |
| Safety and tolerability | 27 | 14 |
| Design and conduct | 21 | 10 |
| Speakers’ debate over adoption and the evidentiary weight of PFS versus OS | 16 | 15 |
| Speakers’ combination-versus-sequencing and component-contribution questions | 22 | 9 |
| Speakers’ interpretations of IMDC patterns and predictive-biomarker needs | 26 | 13 |
| Speakers’ patient-reported outcomes and patient-goal interpretations | 23 | 14 |
| Speakers’ prior-treatment, reimbursement and treatment-line preservation concerns | 30 | 14 |
| Earlier HIF-2α combination evidence and speakers’ development expectations | 29 | 18 |
| Post-IO alternatives, response urgency and trial-referral decisions | 41 | 9 |
| Post-PD-1 rechallenge, treatment withdrawal and local deferral of systemic switching | 45 | 8 |
| Belzutifan-associated anemia: speakers’ work-up, ESA use and counseling | 28 | 6 |
| Belzutifan-associated hypoxia: speakers’ monitoring and interruption practices | 26 | 7 |
| Belzutifan selection: speakers’ VHL-testing and broader profiling debate | 23 | 4 |
| Casdatifan and PEAK-1: alternative-development comparisons and their limits | 26 | 8 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
1422 verified statements from 239 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 1059 statements · 74% | ||||
| YouTube | 288 | 22 | 23 | |
| X videos | 5 | 1 | 1 | |
| Podcasts | 766 | 23 | 24 | |
| Posts · 341 statements · 24% | ||||
| X threads | 301 | 171 | 365 | |
| LinkedIn posts | 33 | 11 | 12 | |
| Bluesky threads | 7 | 7 | 36 | |
| Primary sources · 22 statements · 2%cited for context, not screened | ||||
| Publications | 21 | 3 | — | |
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 141 / quarter
- Screened window
- Oct 23, 2020 → Nov 17, 2026
- Cited window
- Sep 12, 2022 → Nov 14, 2026
- Retrieved
- Nov 19, 2026
The trial
from ClinicalTrials.gov- Title
- An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
- Registry
- NCT04586231
- Study IDs
- 6482-011 · MK-6482-011 (MSD) · jRCT2031210311 (jRCT(Japan Registry of Clinical Trials)) · 2024-510620-39-00 (EU CT) · U1111-1302-2815 (UTN) · 2020-002075-35
- Sponsor
- Merck Sharp & Dohme LLC
- Collaborators
- Eisai Inc.
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 747 actual
- Registered
- 2020-10-14
- Start
- 2021-02-25 actual
- Primary completion
- 2026-02-02 actual
- Primary endpoints
- Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Interventions
- 3 registered
More on: Renal cell carcinoma, belzutifan, lenvatinib
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 2 matching sources (1 podcast, 1 X thread) could not be read and are not included.
- For 3 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on interpreting combination-treatment evidence and individual drug contributions after prior immunotherapy in advanced renal cell carcinoma; a view on emerging post-immunotherapy combinations for subsequent treatment selection in advanced renal cell carcinoma; a view on interpreting efficacy and survival evidence for combination therapy after checkpoint inhibitor progression in advanced renal cancer; a view on real-world evidence supporting cabozantinib as a sequencing option in previously treated advanced renal cell carcinoma; a view on how frontline regimen selection and tolerability shape subsequent treatment options in advanced renal cell carcinoma; a view on salvage kinase inhibition after immunotherapy progression versus upfront triplet therapy; a view on early anemia and hypoxia monitoring and supportive care during belzutifan treatment; a view on distinguishing reported evidence from personal clinical interpretation of combination therapy after immunotherapy in advanced kidney cancer; a view on exploratory biomarkers for selecting patients for belzutifan treatment in previously treated advanced renal cell carcinoma; a view on exploratory biomarkers that may inform patient selection for belzutifan treatment in renal cell carcinoma; a view on efficacy and tolerability requirements for combination treatment versus sequential therapy in advanced renal cell carcinoma; a view on belzutifan monotherapy efficacy, tolerability and quality of life as context for combination treatment after immunotherapy.
- 117 passages in 2 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
Show all 19 known gaps +Fewer −
- 510 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 3 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative survey of HCPs. Their number cannot establish the prevalence of a view, prescribing uptake or professional consensus.
- Some discussions appear in multiple recordings, summaries, reposts or quoted posts. Repetition and redistribution are not additional independent clinical endorsements.
- Some source material could not be read reliably, and portions of several long discussions were not fully assessed. Relevant views, qualifications or answers may therefore be missing.
- Discovery relied partly on trial identifiers and known names. Discussions using unnamed references, unusual abbreviations or different transcriptions may not have been found.
- Several passages cannot be attributed to a named individual with confidence. They remain observations made in the discussion and must not be counted as another participant agreeing or disagreeing with a named speaker.
- The material spans prospective expectations, interim interpretations, final-analysis discussions and approval-related reactions. Those time-specific views should not be combined into an apparent change of mind or treated as equally mature assessments.
- Speakers sometimes give different numerical summaries, study names, toxicity definitions, discontinuation denominators or descriptions of prior treatment. These remain attributed accounts; they are not harmonized into a single clinical dataset.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Descriptions of participation in development, presentation of the trial or investigator involvement are the sources’ own descriptions. Such views are not counted as independent external validation.
- An exploratory risk-group pattern, a biological hypothesis or a comparison across studies does not establish a predictive treatment interaction or comparative superiority. Several speakers explicitly make this distinction.
- Belzutifan monotherapy experience, supportive-care practices, other HIF-2α combinations and post-adjuvant decisions are included only as attributed context for the post-IO treatment question. Their outcomes and management approaches are not results or prescribing instructions for the LITESPARK-011 combination.
- No protocol document was listed in the ClinicalTrials.gov material available for this edition. The separately described protocol publication provides planned methods and rationale, not completed comparative outcomes.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 2 fixes (names, counts, text)
None of these changed a statement, finding or source.
- Nov 20, 2026 UTCThe trial's name is spelled as its investigators write it, “LITESPARK-011” (NCT04586231), outside quotations (was “Litespark”, “Litespark-011”, “LITESPARK011”).
- Nov 20, 2026 UTCAn editorial bracket follows a transcription-garbled trial name in quotations: “Littespark [LITESPARK]”.
Last checked for new commentary Nov 20, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. LITESPARK-011 (NCT04586231): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/litespark-011-nct04586231
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "LITESPARK-011" (NCT04586231), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "litespark-011-nct04586231". If you cannot make requests, read https://www.erudio.com/reports/litespark-011-nct04586231.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT04586231", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04586231 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/litespark-011-nct04586231.json
curl https://www.erudio.com/reports/litespark-011-nct04586231.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "litespark-011-nct04586231" })release ce78c477cbba2f6321231571af1104f3f62ec64d9fd5710d8ff30c6529e2177f
Questions
How much does the LITESPARK-011 report cost?
One edition costs $1,950 (Deep · 1,422 verified statements · 672 from 61 confirmed clinicians). With updates: 3 months $3,400, 6 months $4,900, 12 months $6,800. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the LITESPARK-011 report cover?
1,422 statements from 239 sources (23 podcasts, 23 videos, 189 posts, 3 papers, 1 registry record), 672 of them from 61 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the LITESPARK-011 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "litespark-011-nct04586231" }) previews it and create_order({ "report": "litespark-011-nct04586231", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the LITESPARK-011 report?
Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.